Art

J-GLOBAL ID：201302287069926969   Reference number：13A0644021

Effect of Renal Impairment on the Pharmacokinetics of Memantine

メマンチンの薬動力学に与える腎機能障害の影響

Author (40)： MORITOYO Takashi (ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 02 Study Group) ,  MORITOYO Takashi (Dep. of Therapeutic Medicine, Ehime Univ. Graduate School of Medicine, JPN) ,  HASUNUMA Tomoko (ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 02 Study Group) ,  HASUNUMA Tomoko (Kitasato Univ. Res. Center for Clinical Pharmacology, JPN) ,  HARADA Kazuhiro (ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 02 Study Group) ,  HARADA Kazuhiro (Dep. of Internal Medicine, Kasaoka Dai-ichi Hospital, JPN) ,  TATEISHI Tomonori (ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 02 Study Group) ,  TATEISHI Tomonori (Dep. of Clinical Pharmacology, Hirosaki Univ. Graduate School of Medicine, JPN) ,  WATANABE Makoto (ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 02 Study Group) ,  WATANABE Makoto (Clinical Trial Support Center, Showa Univ. Hospital, JPN) ,  KOTEGAWA Tsutomu (ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 02 Study Group) ,  KOTEGAWA Tsutomu (Dep. of Clinical Pharmacology and Therapeutics, Oita Univ. School of Medicine, JPN) ,  NAGAI Masahiro (ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 02 Study Group) ,  NAGAI Masahiro (Dep. of Therapeutic Medicine, Ehime Univ. Graduate School of Medicine, JPN) ,  KUMAGAI Yuji (ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 02 Study Group) ,  KUMAGAI Yuji (Clinical Trial Center, Kitasato Univ. East Hospital, JPN) ,  FUJITANI Tomomichi (Asubio Pharma Co., Ltd., JPN) ,  OKURA Takahumi (ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 02 Study Group) ,  OKURA Takahumi (Dep. of Integrated Medicine and Informatics, Ehime Univ. Graduate School of Medicine, JPN) ,  FUKUOKA Tomikazu (ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 02 Study Group) ,  FUKUOKA Tomikazu (Dep. of Integrated Medicine and Informatics, Ehime Univ. Graduate School of Medicine, JPN) ,  MIYOSHI Kenichi (ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 02 Study Group) ,  MIYOSHI Kenichi (Dep. of Integrated Medicine and Informatics, Ehime Univ. Graduate School of Medicine, JPN) ,  MATSUURA Bunzo (ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 02 Study Group) ,  MATSUURA Bunzo (Dep. of Gastroenterology and Metabology, Ehime Univ. Graduate School of Medicine, JPN) ,  FURUKAWA Shinya (ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 02 Study Group) ,  FURUKAWA Shinya (Dep. of Gastroenterology and Metabology, Ehime Univ. Graduate School of Medicine, JPN) ,  KOBORI Tomoe (ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 02 Study Group) ,  KOBORI Tomoe (Dep. of Gastroenterology and Metabology, Ehime Univ. Graduate School of Medicine, JPN) ,  MORITOYO Hiroyoko (ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 02 Study Group) ,  MORITOYO Hiroyoko (Dep. of Therapeutic Medicine, Ehime Univ. Graduate School of Medicine, JPN) ,  NISHIKAWA Noriko (ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 02 Study Group) ,  NISHIKAWA Noriko (Dep. of Therapeutic Medicine, Ehime Univ. Graduate School of Medicine, JPN) ,  TSUJII Tomoaki (ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 02 Study Group) ,  TSUJII Tomoaki (Dep. of Therapeutic Medicine, Ehime Univ. Graduate School of Medicine, JPN) ,  IWAKI Hirotaka (ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 02 Study Group) ,  IWAKI Hirotaka (Dep. of Therapeutic Medicine, Ehime Univ. Graduate School of Medicine, JPN) ,  NAKAMURA Masahiko (ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 02 Study Group) ,  NAKAMURA Masahiko (Kitasato Univ. Res. Center for Clinical Pharmacology, JPN) ,  MAKINO Satoshi (ANTCliPh (Academic Network for Trials in Clinical Pharmacology) Trial 02 Study Group)
Material： Journal of Pharmacological Sciences  (J Pharmacol Sci)
Volume： 119  Issue： 4  Page： 324-329 (J-STAGE)  Publication year： 2012 
JST Material Number： G0813A  ISSN： 1347-8613  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： *antiparkinson drug ,...
Semi thesaurus term： *maximum blood concentration

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=13A0644021&from=J-GLOBAL&jstjournalNo=G0813A") }}

JST classification (3)： Clinical application of other drugs acting on central nervous system  (GW03130F) ,  Physicochemical characteristics of drugs  (GV01060M) ,  Clinical medicine on urogenital system in general  (GM01030E)

Substance index (1)： Memantine

Reference (12)：

• 1 Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ; Memantine Study Group. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348:1333–1341.
• 2 Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007;6:782–792.
• 3 Emre M, Tsolaki M, Bonuccelli U, Destée A, Tolosa E, Kutzelnigg A, et al; 11018 Study Investigators. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:969–977.
• 4 Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson’s disease: a double-blind crossover randomized study. Clin Neuropharmacol. 1999;22:273–276.
• 5 Wesemann W, Sonntag K-M, Maj J. [Pharmacodynamics and pharmacokinetics of memantine]. Drug Res. 1983;33:1122–1134. (text in German with English abstract)

Terms in the title (3)： メマンチン ,  薬動力学 ,  腎機能障害